Why BioNTech SE - ADR’s (BNTX) Stock Is Down 7.29%

By AAII Staff
September 18, 2024
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BioNTech SE - ADR before investing.

In this article, we go over a few key elements for understanding BioNTech SE - ADR’s stock price such as:

  • BioNTech SE - ADR’s current stock price and volume
  • Why BioNTech SE - ADR’s stock price changed recently
  • Upgrades and downgrades for BNTX from analysts
  • BNTX’s stock price momentum as measured by its relative strength

About BioNTech SE - ADR (BNTX)

Before we jump into BioNTech SE - ADR’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Want to learn more about BioNTech SE - ADR’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BioNTech SE - ADR.

Learn More About A+ Investor

BioNTech SE - ADR’s Stock Price as of Market Close

As of September 18, 2024, 4:00 PM, CST, BioNTech SE - ADR’s stock price was $115.62.

BioNTech SE - ADR is down 7.29% from its previous closing price of $124.71.

During the last market session, BioNTech SE - ADR’s stock traded between $121.88 and $131.49. Currently, there are 240.42 million shares of BioNTech SE - ADR stock available for purchase.

Unfortunately, BioNTech SE - ADR’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

BioNTech SE - ADR Stock Price History

BioNTech SE - ADR’s (BNTX) price is currently up 31.06% so far this month.

During the month of September, BioNTech SE - ADR’s stock price has reached a high of $131.49 and a low of $86.45.

Over the last year, BioNTech SE - ADR has hit prices as high as $131.49 and as low as $76.53. Year to date, BioNTech SE - ADR’s stock is down 23.03%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BioNTech SE - ADR Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 17, 2024, there was 1 analyst who downgraded BioNTech SE - ADR’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BioNTech SE - ADR’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BioNTech SE - ADR’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BioNTech SE - ADR’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BioNTech SE - ADR (BNTX) by visiting AAII Stock Evaluator.

Relative Price Strength of BioNTech SE - ADR

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 17, 2024, BioNTech SE - ADR has a weighted four-quarter relative price strength of 7.98%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how BioNTech SE - ADR is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BioNTech SE - ADR Stock Price: Bottom Line

As of September 18, 2024, BioNTech SE - ADR’s stock price is $115.62, which is down 7.29% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BioNTech SE - ADR stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
O'Neil CAN SLIM Screen: 38.3% Compared to S&P 500
at only 23.3%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.